Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Rythmodan is used in the treatment of cardiac arrhythmias as follows:
Posology – Oral: 300 mg to 800mg daily in divided doses.
Elderly: A dose reduction due to reduced renal and hepatic function in the elderly (especially elderly non-smokers) should be considered (see section 4.4).
Paediatric population: The safety and efficacy of disopyramide in children less than 18 years has not been established. Current available evidence is available in section 4.4, 5.1 and 5.2.
Toxic plasma levels are reflected by ECG abnormalities such as:
The clinical signs of overdose may include:
Apart from prostigmine derivatives which can be used to treat anticholinergic effects, there is no specific antidote for disopyramide.
Treatment of acute overdose should be carried out in an intensive care unit under continuous cardiac monitoring. Monitor vital signs and measure blood sugar, serum potassium, magnesium and calcium concentrations.
Symptomatic supportive measures may include:
Glass Bottle: 36 months.
PVC Blister: 36 months.
Do not store above 25°C.
Glass Bottle containing 100 capsules.
PVC Blister containing 84 capsules.
Amber glass bottle with jaycap closure containing 100 capsules.
PVC/PVdC blister strips in cardboard cartons containing 84 capsules.
None.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.